Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Omeros (OMER) Notes Payables (2010 - 2012)

Omeros recorded quarterly Notes Payables of $6.4 million in Q3 2012, up 2.62% quarter-over-quarter from $6.2 million in Q2 2012, and up 20.82% year-over-year from $5.3 million in Q4 2011.

Omeros' Notes Payables history runs 3 years deep, the most recent figure standing at $6.4 million for Q3 2012.

  • In Q3 2012, Notes Payables rose 20.82% year-over-year to $6.4 million; the TTM figure through Sep 2012 stood at $6.4 million (up 20.82% YoY), while the FY2011 annual figure was $5.9 million, up 1392.41% from the prior year.
  • Notes Payables came in at $6.4 million for Q3 2012 at Omeros, up from $6.2 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $6.4 million in Q3 2012 to a low of $395000.0 in Q4 2010.
  • A 3-year average of $4.8 million and a median of $5.9 million in 2011 frame the typical range for Notes Payables.
  • Across the five-year window, Notes Payables jumped 1392.41% in 2011 and climbed 20.82% in 2012, its largest moves.
  • Omeros' Notes Payables stood at $395000.0 in 2010, then surged by 1392.41% to $5.9 million in 2011, then grew by 8.11% to $6.4 million in 2012.
  • According to Business Quant data, Notes Payables over the past three periods registered $6.4 million, $6.2 million, and $6.0 million for Q3 2012, Q2 2012, and Q1 2012 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Omeros 772.03 Mn 636.71 Mn 9.31 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2012 6.37 Mn
Jun 30, 2012 6.21 Mn
Mar 31, 2012 6.05 Mn
Dec 31, 2011 5.90 Mn
Sep 30, 2011 5.28 Mn
Jun 30, 2011 3.72 Mn
Dec 31, 2010 395,000.00